1. CV Risk Management in T2DM: What Did We Learn from ADA 2016?

2. Program Overview

3. ADA Scientific Sessions

4. T2DM and CVD

5. Progression to Diabetes Is Associated With an Increased Incidence of CVD Among Persons With IGT

6. Impact of Progression to Diabetes on CVD Events

7. Glucose-Lowering and Vascular Benefits

8. Safety of Glucose-Lowering Drugs

9. Ongoing CVOTs in Patients With T2DM

10. Mortality Findings From the EXAMINE Trial[a]

11. EXAMINE: CV Mortality Findings

12. EMPA-REG OUTCOME: Primary Endpoint -- 3-Point MACE*

13. Effect of Empagliflozin on CV Death in Subgroups by Age: Results From EMPA-REG OUTCOME

14. Effect of Empagliflozin on HF Outcomes in Subgroups by Age: Results From EMPA-REG OUTCOME

15. Incidence Rates of CV Death by LDL-C at Baseline

16. LEADER: Study Design

17. LEADER: Primary and Key Secondary Outcomes

18. LEADER: Study Population Baseline Characteristics

19. LEADER: Primary Outcome*

20. LEADER: Primary Outcome Subgroup Analyses

21. LEADER: Primary Outcome Subgroup Analyses (cont)

22. LEADER: CV Death

23. LEADER: All-Cause Death

24. LEADER: Time to Nonfatal MI

25. LEADER: Time to Nonfatal Stroke

26. LEADER: Hospitalization for HF

27. LEADER: AEs Leading to Permanent Treatment Discontinuation

28. LEADER: Selected AEs of Special Interest

29. LEADER: Risk for Hypoglycemia

30. SUSTAIN 6

31. Conclusions

32. Conclusions (cont)

33. Abbreviations

34. Abbreviations (cont)